Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ATDC induces an invasive switch in KRAS-induced pancreatic tumorigenesis.
Wang L, Yang H, Abel EV, Ney GM, Palmbos PL, Bednar F, Zhang Y, Leflein J, Waghray M, Owens S, Wilkinson JE, Prasad J, Ljungman M, Rhim AD, Pasca di Magliano M, Simeone DM. Wang L, et al. Among authors: leflein j. Genes Dev. 2015 Jan 15;29(2):171-83. doi: 10.1101/gad.253591.114. Genes Dev. 2015. PMID: 25593307 Free PMC article.
ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates radioresistance in pancreatic cancer cells.
Wang L, Yang H, Palmbos PL, Ney G, Detzler TA, Coleman D, Leflein J, Davis M, Zhang M, Tang W, Hicks JK, Helchowski CM, Prasad J, Lawrence TS, Xu L, Yu X, Canman CE, Ljungman M, Simeone DM. Wang L, et al. Among authors: leflein j. Cancer Res. 2014 Mar 15;74(6):1778-88. doi: 10.1158/0008-5472.CAN-13-2289. Epub 2014 Jan 27. Cancer Res. 2014. PMID: 24469230 Free PMC article.
ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms.
Palmbos PL, Wang L, Yang H, Wang Y, Leflein J, Ahmet ML, Wilkinson JE, Kumar-Sinha C, Ney GM, Tomlins SA, Daignault S, Kunju LP, Wu XR, Lotan Y, Liebert M, Ljungman ME, Simeone DM. Palmbos PL, et al. Among authors: leflein j. Cancer Res. 2015 Dec 1;75(23):5155-66. doi: 10.1158/0008-5472.CAN-15-0603. Epub 2015 Oct 15. Cancer Res. 2015. PMID: 26471361 Free PMC article.
ATDC mediates a TP63-regulated basal cancer invasive program.
Palmbos PL, Wang Y, Bankhead Iii A, Kelleher AJ, Wang L, Yang H, Ahmet ML, Gumkowski ER, Welling SD, Magnuson B, Leflein J, Lorenzatti Hiles G, Abel EV, Dziubinski ML, Urs S, Day ML, Ljungman ME, Simeone DM. Palmbos PL, et al. Among authors: leflein j. Oncogene. 2019 May;38(18):3340-3354. doi: 10.1038/s41388-018-0646-9. Epub 2019 Jan 14. Oncogene. 2019. PMID: 30643195 Free PMC article.
Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study.
Sindher SB, Nadeau KC, Chinthrajah RS, Leflein JG, Bégin P, Ohayon JA, Ponda P, Wambre E, Liu J, Khokhar FA, Akinlade B, Maloney J, Orengo JM, Hamilton JD, Kamal MA, Hooper AT, Patel N, Patel K, Laws E, Mannent LP, Radin AR. Sindher SB, et al. Among authors: leflein jg. Allergy. 2024 Dec 14. doi: 10.1111/all.16404. Online ahead of print. Allergy. 2024. PMID: 39673452
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy.
Chinthrajah RS, Sindher SB, Nadeau KC, Leflein JG, Spergel JM, Petroni DH, Jones SM, Casale TB, Wang J, Carr WW, Shreffler WG, Wood RA, Wambre E, Liu J, Akinlade B, Atanasio A, Orengo JM, Hamilton JD, Kamal MA, Hooper AT, Patel K, Laws E, Mannent LP, Adelman DC, Ratnayake A, Radin AR. Chinthrajah RS, et al. Among authors: leflein jg. Allergy. 2024 Dec 14. doi: 10.1111/all.16420. Online ahead of print. Allergy. 2024. PMID: 39673367
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.
Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, Chen R, Saito J, de Luíz Martinez G, Dymek L, Jacques L, Bird N, Schalkwijk S, Smith D, Howarth P, Pavord ID; SWIFT-1 and SWIFT-2 Investigators; SWIFT-1 Investigators; SWIFT-2 Investigators. Jackson DJ, et al. N Engl J Med. 2024 Dec 19;391(24):2337-2349. doi: 10.1056/NEJMoa2406673. Epub 2024 Sep 9. N Engl J Med. 2024. PMID: 39248309 Clinical Trial.
Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial.
Altrichter S, Giménez-Arnau AM, Bernstein JA, Metz M, Bahadori L, Bergquist M, Brooks L, Ho CN, Jain P, Lukka PB, Rodriguez-Suárez E, Walton C, Datto CJ; ARROYO Study Investigators. Altrichter S, et al. Br J Dermatol. 2024 Jul 16;191(2):187-199. doi: 10.1093/bjd/ljae067. Br J Dermatol. 2024. PMID: 38367194 Clinical Trial.
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Among authors: leflein j. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial.
Guttman-Yassky E, Bahadori L, Brooks L, Clark KL, Grindebacke H, Ho CN, Katial R, Pham TH, Walton C, Datto CJ; HILLIER study group†. Guttman-Yassky E, et al. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):e1211-e1214. doi: 10.1111/jdv.19195. Epub 2023 Jun 12. J Eur Acad Dermatol Venereol. 2023. PMID: 37178404 Clinical Trial. No abstract available.
29 results